Cargando…
Direct control of CAR T cells through small molecule-regulated antibodies
Antibody-based therapeutics have experienced a rapid growth in recent years and are now utilized in various modalities spanning from conventional antibodies, antibody-drug conjugates, bispecific antibodies to chimeric antigen receptor (CAR) T cells. Many next generation antibody therapeutics achieve...
Autores principales: | Park, Spencer, Pascua, Edward, Lindquist, Kevin C., Kimberlin, Christopher, Deng, Xiaodi, Mak, Yvonne S. L., Melton, Zea, Johnson, Theodore O., Lin, Regina, Boldajipour, Bijan, Abraham, Robert T., Pons, Jaume, Sasu, Barbra Johnson, Van Blarcom, Thomas J., Chaparro-Riggers, Javier |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7846603/ https://www.ncbi.nlm.nih.gov/pubmed/33514714 http://dx.doi.org/10.1038/s41467-020-20671-6 |
Ejemplares similares
-
A Versatile Safeguard for Chimeric Antigen Receptor T-Cell Immunotherapies
por: Valton, Julien, et al.
Publicado: (2018) -
Allogeneic Anti-BCMA CAR T Cells Are Superior to Multiple Myeloma-derived CAR T Cells in Preclinical Studies and May Be Combined with Gamma Secretase Inhibitors
por: Metelo, Ana M., et al.
Publicado: (2022) -
Constitutive Turbodomains enhance expansion and antitumor activity of allogeneic BCMA CAR T cells in preclinical models
por: Lin, Regina J., et al.
Publicado: (2023) -
Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity
por: Chen, Shih-Hsun, et al.
Publicado: (2021) -
One size does not fit all: navigating the multi-dimensional space to optimize T-cell engaging protein therapeutics
por: Chen, Wei, et al.
Publicado: (2021)